Activation of AMP-kinase by AICAR induces apoptosis of DU-145 prostate cancer cells through generation of reactive oxygen species and activation of c-Jun N-terminal kinase

International Journal of Oncology

Volumn 40, Issue 2, 2012, Pages 501-508

  Sauer, Heinrich ^a   Engel, Steffi ^a   Milosevic, Nada ^a   Sharifpanah, Fatemeh ^a   Wartenberg, Maria ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

AMPK; Apoptosis; c jun N terminal kinase; DU 145; mTOR; Prostate; Reactive oxygen species

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENYLATE KINASE; CASPASE 3; MAMMALIAN TARGET OF RAPAMYCIN; REACTIVE OXYGEN METABOLITE; ROTENONE; STRESS ACTIVATED PROTEIN KINASE; TIOPRONIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INCUBATION TIME; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

ADENYLATE KINASE; AMINOIMIDAZOLE CARBOXAMIDE; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME ACTIVATORS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; RIBONUCLEOTIDES; TOR SERINE-THREONINE KINASES;

EID: 84855713153     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1230     Document Type: Article

References (41)

1. Swinnen JV, Beckers A, Brusselmans K, et al: Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype. Cancer Res 65: 2441-2448, 2005. (Pubitemid 40490156)
2. Flavin R, Zadra G and Loda M: Metabolic alterations and targeted therapies in prostate cancer. J Pathol 223: 283-294, 2011.
3. Hardie DG: AMPK and autophagy get connected. EMBO J 30: 634-635, 2011.
4. Shackelford DB and Shaw RJ: The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 9: 563-575, 2009.
5. Gwinn DM, Shackelford DB, Egan DF, et al: AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30: 214-226, 2008. (Pubitemid 351626684)
6. Pradelli LA, Beneteau M, Chauvin C, et al: Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation. Oncogene 29: 1641-1652, 2010.
7. Woodard J, Joshi S, Viollet B, Hay N and Platanias LC: AMPK as a therapeutic target in renal cell carcinoma. Cancer Biol Ther 10: 1168-1177, 2010.
8. Woodard J and Platanias LC: AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival. Biochem Biophys Res Commun 398: 135-139, 2010.
9. Theodoropoulou S, Kolovou PE, Morizane Y, et al: Retinoblastoma cells are inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase. FASEB J 24: 2620-2630, 2010.
10. Guo D, Hildebrandt IJ, Prins RM, et al: The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci USA 106: 12932-12937, 2009.
11. Sengupta TK, Leclerc GM, Hsieh-Kinser TT, Leclerc GJ, Singh I and Barredo JC: Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol Cancer 6: 46, 2007.
12. Xiang X, Saha AK, Wen R, Ruderman NB and Luo Z: AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 321: 161-167, 2004. (Pubitemid 39055618)
13. Zhuge J: Overexpression of CYP2E1 induces HepG2 cells death by the AMP kinase activator 5′-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR). Cell Biol Toxicol 25: 253-263, 2009.
14. Isakovic A, Harhaji L, Stevanovic D, et al: Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci 64: 1290-1302, 2007. (Pubitemid 46791062)
15. Cai Y, Martens GA, Hinke SA, Heimberg H, Pipeleers D and van De CM: Increased oxygen radical formation and mitochondrial dysfunction mediate beta cell apoptosis under conditions of AMP-activated protein kinase stimulation. Free Radic Biol Med 42: 64-78, 2007. (Pubitemid 44839152)
16. Kim EK and Choi EJ: Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802: 396-405, 2010.
17. Jung JE, Lee J, Ha J, Kim SS, Cho YH, Baik HH and Kang I: 5-Aminoimidazole-4-carboxamide-ribonucleoside enhances oxidative stress-induced apoptosis through activation of nuclear factor-kappaB in mouse Neuro 2a neuroblastoma cells. Neurosci Lett 354: 197-200, 2004. (Pubitemid 38045343)
18. Jose C, Hebert-Chatelain E, Bellance N, Larendra A, Su M, Nouette-Gaulain K and Rossignol R: AICAR inhibits cancer cell growth and triggers cell-type distinct effects on OXPHOS biogenesis, oxidative stress and Akt activation. Biochim Biophys Acta 1807: 707-718, 2011.
19. Sauer H, Wartenberg M and Hescheler J: Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem 11: 173-186, 2001. (Pubitemid 32786086)
20. Kim JE, Kim YW, Lee IK, Kim JY, Kang YJ and Park SY: AMP-activated protein kinase activation by 5-aminoimidazole-4-carboxamide-1-beta-D- ribofuranoside (AICAR) inhibits palmitate-induced endothelial cell apoptosis through reactive oxygen species suppression. J Pharmacol Sci 106: 394-403, 2008.
21. Wang S, Zhang M, Liang B, et al: AMPKalpha2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes. Circ Res 106: 1117-1128, 2010.
22. Green AS, Chapuis N, Lacombe C, Mayeux P, Bouscary D and Tamburini J: LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology. Cell Cycle (In press).
23. Easton JB and Houghton PJ: Therapeutic potential of target of rapamycin inhibitors. Expert Opin Ther Targets 8: 551-564, 2004. (Pubitemid 40028366)
24. Fasolo A and Sessa C: Current and future directions in mammalian target of rapamycin inhibitors development. Expert Opin Investig Drugs 20: 381-394, 2011.
25. Wander SA, Hennessy BT and Slingerland JM: Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 121: 1231-1241, 2011.
26. Misra P and Chakrabarti R: The role of AMP kinase in diabetes. Indian J Med Res 125: 389-398, 2007. (Pubitemid 46805453)
27. Leverve XM, Guigas B, Detaille D, et al: Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab 29: S688-S694, 2003.
28. Chang MY, Ho FM, Wang JS, Kang HC, Chang Y, Ye ZX and Lin WW: AICAR induces cyclooxygenase-2 expression through AMP-activated protein kinase-transforming growth factor-beta-activated kinase 1-p38 mitogen-activated protein kinase signaling pathway. Biochem Pharmacol 80: 1210-1220, 2010.
29. Ji WT, Lee LH, Lin FL, Wang L and Liu HJ: AMP-activated protein kinase facilitates avian reovirus to induce mitogen-activated protein kinase (MAPK) p38 and MAPK kinase 3/6 signalling that is beneficial for virus replication. J Gen Virol 90: 3002-3009, 2009.
30. McConell GK, Ng GP, Phillips M, Ruan Z, Macaulay SL and Wadley GD: Central role of nitric oxide synthase in AICAR and caffeine-induced mitochondrial biogenesis in L6 myocytes. J Appl Physiol 108: 589-595, 2010.
31. Henry BA, Andrews ZB, Rao A and Clarke IJ: Central leptin activates mitochondrial function and increases heat production in skeletal muscle. Endocrinology 152: 2609-2618, 2011.
32. Li XN, Song J, Zhang L, et al: Activation of the AMPK-FOXO3 pathway reduces fatty acid-induced increase in intracellular reactive oxygen species by upregulating thioredoxin. Diabetes 58: 2246-2257, 2009.
33. Irrcher I, Ljubicic V and Hood DA: Interactions between ROS and AMP kinase activity in the regulation of PGC-1alpha transcription in skeletal muscle cells. Am J Physiol Cell Physiol 296: C116-C123, 2009.
34. Xie Z, Zhang J, Wu J, Viollet B and Zou MH: Upregulation of mitochondrial uncoupling protein-2 by the AMP-activated protein kinase in endothelial cells attenuates oxidative stress in diabetes. Diabetes 57: 3222-3230, 2008.
35. Adachi M and Brenner DA: High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. Hepatology 47: 677-685, 2008. (Pubitemid 351280736)
36. Wang Q, Liang B, Shirwany NA and Zou MH: 2-Deoxy-D-glucose treatment of endothelial cells induces autophagy by reactive oxygen species-mediated activation of the AMP-activated protein kinase. PLoS One 6: e17234, 2011.
37. Hwang JT, Park OJ, Lee YK, et al: Anti-tumor effect of luteolin is accompanied by AMP-activated protein kinase and nuclear factor-kappaB modulation in HepG2 hepatocarcinoma cells. Int J Mol Med 28: 25-31, 2011.
38. Zhang M, Dong Y, Xu J, et al: Thromboxane receptor activates the AMP-activated protein kinase in vascular smooth muscle cells via hydrogen peroxide. Circ Res 102: 328-337, 2008. (Pubitemid 351271653)
39. Emerling BM, Weinberg F, Snyder C, et al: Hypoxic activation of AMPK is dependent on mitochondrial ROS but independent of an increase in AMP/ATP ratio. Free Radic Biol Med 46: 1386-1391, 2009.
40. Toyoda T, Hayashi T, Miyamoto L, et al: Possible involvement of the alpha1 isoform of 5′AMP-activated protein kinase in oxidative stress-stimulated glucose transport in skeletal muscle. Am J Physiol Endocrinol Metab 287: E166-E173, 2004. (Pubitemid 38856297)
41. Zmijewski JW, Banerjee S, Bae H, Friggeri A, Lazarowski ER and Abraham E: Exposure to hydrogen peroxide induces oxidation and activation of AMP-activated protein kinase. J Biol Chem 285: 33154-33164, 2010.